[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Item 1. Condensed Consolidated Financial Statements](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) The unaudited condensed consolidated financial statements for the period ended September 30, 2023, show a significant increase in net loss and a substantial decrease in cash and stockholders' equity compared to the previous year, raising doubt about the company's going concern ability as existing cash is projected to fund operations only into the first quarter of 2024 [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2023, the company's total assets decreased to $16.2 million from $31.3 million at year-end 2022, primarily due to a significant reduction in cash and cash equivalents, while total liabilities increased and total stockholders' equity fell sharply from $26.6 million to $9.1 million Condensed Consolidated Balance Sheets (unaudited) | | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | $12,687,041 | $27,612,732 | | Total current assets | $14,800,290 | $28,938,730 | | **Total Assets** | **$16,201,031** | **$31,347,928** | | **Current Liabilities** | | | | Total current liabilities | $7,081,685 | $4,747,894 | | **Total Stockholders' Equity** | **$9,119,346** | **$26,600,034** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three and nine months ended September 30, 2023, the company reported significantly higher net losses compared to the same periods in 2022, driven by a substantial rise in research and development expenses, which more than doubled year-over-year Statements of Operations Highlights (unaudited) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Grant Revenue | $0 | $0 | $0 | $81,526 | | Research and Development | $6,947,979 | $2,721,196 | $14,486,896 | $5,358,917 | | General and Administrative | $1,651,775 | $1,249,337 | $4,562,293 | $3,363,672 | | **Net Loss** | **$(8,408,818)** | **$(3,968,102)** | **$(18,374,354)** | **$(8,637,316)** | | Net Loss Per Share | $(0.32) | $(0.17) | $(0.69) | $(0.63) | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) Stockholders' equity decreased from $26.6 million at the end of 2022 to $9.1 million by September 30, 2023, primarily driven by the cumulative net loss of $18.4 million for the nine-month period, slightly offset by stock-based compensation and stock issuances for services - Total stockholders' equity declined from **$26,600,034** at December 31, 2022, to **$9,119,346** at September 30, 2023[15](index=15&type=chunk) - The primary driver for the decrease in equity was the net loss of **$18,374,354** for the nine months ended September 30, 2023[13](index=13&type=chunk)[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended September 30, 2023, net cash used in operating activities increased to $14.9 million from $12.0 million in the prior year period, with no financing activities in 2023 unlike 2022's $35.4 million, leading to a net decrease in cash of $14.9 million Cash Flow Summary (unaudited) | Cash Flow Activity | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(14,895,694) | $(11,965,972) | | Net cash used in investing activities | $(29,997) | $(134,258) | | Net cash provided by financing activities | $0 | $35,353,328 | | **Net (decrease) increase in cash** | **$(14,925,691)** | **$23,253,098** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes highlight the company's focus on developing immunotherapies and vaccines, crucially stating that existing cash resources are only sufficient to fund operations into Q1 2024, raising substantial doubt about the company's ability to continue as a going concern, and detailing commitments under operating leases, license agreements, stock options, and warrants outstanding - The company's existing cash resources are only sufficient to fund planned operations into the first quarter of 2024, which raises substantial doubt about its ability to continue as a going concern[23](index=23&type=chunk) - As of September 30, 2023, there were **2,018,800** stock options and **13,384,115** stock purchase warrants outstanding[32](index=32&type=chunk)[33](index=33&type=chunk) - The company has commitments for an operating lease for office and lab space expiring in December 2025, as well as various technology license agreements with uncertain future payment amounts[27](index=27&type=chunk)[28](index=28&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=11&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's focus as a clinical-stage biotechnology firm and provides updates on its key clinical trials, including GEO-CM04S1 for COVID-19 and Gedeptin for head and neck cancer, highlighting a significant increase in operating expenses, primarily R&D, leading to a larger net loss and major liquidity concerns with cash reserves expected to be depleted by early 2024, necessitating additional funding [Overview and Recent Events](index=11&type=section&id=Overview%20and%20Recent%20Events) GeoVax is advancing its pipeline of immunotherapies and vaccines, with recent developments including positive immunogenicity data for its COVID-19 vaccine (GEO-CM04S1), expansion of its Phase 2 trial sites, completion of enrollment in another booster trial, and safety and feasibility findings for the Gedeptin trial for head and neck cancer, alongside securing a commercial license for a new manufacturing cell line and receiving several Notices of Allowance for new patents - GEO-CM04S1 COVID-19 Vaccine: Phase 2 trial in immunocompromised patients showed high immunogenicity; site expansion is underway to accelerate enrollment. A separate booster trial has completed patient enrollment[42](index=42&type=chunk)[49](index=49&type=chunk) - Gedeptin® Cancer Therapy: Interim data from the Phase 1/2 trial in advanced head and neck cancer indicated safety, feasibility, and observation of tumor growth impairment[49](index=49&type=chunk) - Manufacturing & IP: Signed a commercial license with ProBioGen for its AGE1.CR.pIX® cell line to enhance MVA-based vaccine manufacturing. Received multiple U.S. Patent Office Notices of Allowance for its Marburg, HIV, Malaria, and Ebolavirus vaccine platforms[46](index=46&type=chunk)[50](index=50&type=chunk) [Results of Operations](index=16&type=section&id=Results%20of%20Operations) Comparing the three and nine-month periods ended September 30, 2023, to 2022, the company saw a significant widening of its net loss, primarily driven by a 155% and 170% increase in R&D expenses for the respective periods, attributed to clinical trial costs for GEO-CM04S1 and Gedeptin, while general and administrative expenses also rose by 32% and 36% due to higher personnel, consulting, and legal costs Comparison of Operating Results | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research & Development | $6,947,979 | $2,721,196 | $14,486,896 | $5,358,917 | | General & Administrative | $1,651,775 | $1,249,337 | $4,562,293 | $3,363,672 | | **Net Loss** | **$(8,408,818)** | **$(3,968,102)** | **$(18,374,354)** | **$(8,637,316)** | - R&D expenses increased **170%** for the nine-month period due to costs of clinical trials for GEO-CM04S1 and Gedeptin, manufacturing materials, license fees, and personnel costs[62](index=62&type=chunk) - G&A expenses increased **36%** for the nine-month period due to higher personnel costs, investor relations consulting, legal fees, and patent costs[63](index=63&type=chunk) [Liquidity and Capital Resources](index=17&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity has significantly deteriorated, with cash and cash equivalents dropping to $12.7 million from $27.6 million at the end of 2022, and working capital also decreasing sharply, as the company used $14.9 million in cash for operations during the first nine months of 2023 with no financing activities, in contrast to raising over $35 million in the same period of 2022, necessitating substantial additional funding as current cash will only fund operations into the first quarter of 2024 - Existing cash and cash equivalents are expected to be sufficient to fund operations only into the first quarter of 2024[68](index=68&type=chunk) Liquidity and Capital Resources Summary | Metric | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,687,041 | $27,612,732 | | Working capital | $7,718,605 | $24,190,836 | - Net cash used in operating activities was **$14.9 million** for the nine months ended September 30, 2023. There were no cash proceeds from financing activities during this period, compared to **$35.4 million** in the prior year period[65](index=65&type=chunk)[66](index=66&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=18&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section is not applicable as the company qualifies as a smaller reporting company - Not applicable to smaller reporting companies[71](index=71&type=chunk) [Item 4. Controls and Procedures](index=18&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of September 30, 2023, with no significant changes in internal control over financial reporting during the quarter - Based on an evaluation as of the end of the period, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures are effective[73](index=73&type=chunk) - No significant changes in internal control over financial reporting occurred during the three months ended September 30, 2023[74](index=74&type=chunk) [PART II – OTHER INFORMATION](index=19&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=19&type=section&id=Item%201.%20Legal%20Proceedings) The company reported no legal proceedings - None[77](index=77&type=chunk) [Item 1A. Risk Factors](index=19&type=section&id=Item%201A.%20Risk%20Factors) As a smaller reporting company, GeoVax is not required to provide updates on material changes to risk factors, referring to the risk factors disclosed in its most recent Annual Report on Form 10-K - As a smaller reporting company, GeoVax is not required to provide information on material changes from the risk factors previously disclosed in its most recent Annual Report on Form 10‑K[78](index=78&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=19&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the quarter, the company issued a total of 251,638 shares of restricted common stock in two separate transactions to consultants for professional services, relying on exemptions from registration under the Securities Act - On August 10, 2023, the company issued **178,253** shares of restricted common stock to Outside the Box Capital, Inc. for professional services[79](index=79&type=chunk) - On September 28, 2023, the company issued **73,385** shares of restricted common stock to Acorn Management Partners, LLC for consulting services[80](index=80&type=chunk) [Item 5. Other Information](index=19&type=section&id=Item%205.%20Other%20Information) The company reported that no directors or executive officers adopted or terminated any Rule 10b5-1 trading arrangements during the period - During the reporting period, none of the company's directors or executive officers adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement"[83](index=83&type=chunk) [Item 6. Exhibits](index=20&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including an At The Market Offering Agreement, officer certifications, and Inline XBRL documents - Exhibits filed include an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, certifications from the CEO and CFO, and XBRL data files[85](index=85&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Drive, Suite 380 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

[Part I](index=4&type=section&id=PART%20I) This section provides an overview of GeoVax Labs, Inc.'s business, product pipeline, strategic direction, intellectual property, and key risks [Business](index=4&type=section&id=ITEM%201.%20BUSINESS) GeoVax is a clinical-stage biotech company developing vaccines and immunotherapies for infectious diseases and cancers - **GeoVax is a clinical-stage biotechnology company** developing vaccines and immunotherapies against infectious diseases (COVID-19, MPox, Ebola, Zika) and solid tumor cancers (advanced head and neck cancer)[14](index=14&type=chunk) Product Development Pipeline Status | Indication | Current Status | | :--- | :--- | | **Coronavirus Vaccines** | | | COVID-19 (Booster to mRNA vaccines) | Clinical – Phase 2 | | COVID-19 (Primary for immunocompromised) | Clinical – Phase 2 | | Pan Coronavirus | Preclinical/IND-Enabling | | **Cancer Therapy** | | | Solid Tumors (Advanced Head and Neck Cancer)* | Clinical – Phase 1/2 | | Solid Tumors (MUC1) | Preclinical/IND-Enabling | | **Other Infectious Disease Vaccines** | | | Monkeypox (MPox) & Smallpox (SPox) | Preclinical/IND-Enabling | | Hemorrhagic Fever Viruses (Ebola, Sudan, Marburg, Lassa) | Preclinical/IND-Enabling | | Zika** | Preclinical/IND-Enabling | | Malaria** | Exploratory | *Orphan Drug status granted **Indication within FDA Priority Review Voucher program - The company's core technology is the **GV-MVA-VLP™ platform**, which uses a Modified Vaccinia Ankara (MVA) vector to produce Virus-Like Particles (VLPs) in the recipient, stimulating both humoral and cellular immune responses[52](index=52&type=chunk)[53](index=53&type=chunk) - GeoVax relies on **third-party contract manufacturers** for clinical and commercial supplies and is developing a **proprietary, continuous avian cell line manufacturing system** to improve scalability and reduce costs[75](index=75&type=chunk)[77](index=77&type=chunk) - As of December 31, 2022, the company's intellectual property portfolio includes **over 115 granted or pending patent applications across 24 patent families**, comprising owned, co-owned, and in-licensed assets[14](index=14&type=chunk)[89](index=89&type=chunk) [Risk Factors](index=21&type=section&id=ITEM%201A.RISK%20FACTORS) The company faces substantial financial, operational, and market risks, including ongoing losses, funding needs, and potential Nasdaq delisting - The company has a **history of operating losses**, expects them to continue, and has received a **"going concern" opinion** from its auditors, indicating substantial doubt about its ability to continue operations without raising additional capital[125](index=125&type=chunk)[126](index=126&type=chunk) - Current working capital is projected to be sufficient to support operations only into the **fourth quarter of 2023**, requiring **substantial additional financing** to advance development programs[129](index=129&type=chunk) - The company's product candidates are based on **new medical technology** and are inherently risky, with **no guarantee of safety, efficacy, or regulatory approval**[133](index=133&type=chunk)[137](index=137&type=chunk) - GeoVax received a **deficiency letter from Nasdaq** on December 9, 2022, for its stock price falling below the **$1.00 minimum bid requirement**, posing a **risk of delisting** if compliance is not regained by June 7, 2023[184](index=184&type=chunk)[185](index=185&type=chunk) - The company's success is highly dependent on its ability to **obtain, maintain, and enforce its intellectual property rights**, and it faces **risks of infringement claims** from third parties, particularly in the crowded COVID-19 vaccine space[153](index=153&type=chunk)[157](index=157&type=chunk) [Unresolved Staff Comments](index=33&type=section&id=ITEM%201B.%20UNRESOLVED%20STAFF%20COMMENTS) The company reports that there are no unresolved staff comments from the SEC - There are **no unresolved staff comments**[187](index=187&type=chunk) [Properties](index=33&type=section&id=ITEM%202.%20PROPERTIES) GeoVax leases 8,400 sq ft of office and lab space in Smyrna, Georgia, deeming current facilities adequate - The company's principal executive offices and laboratory are located in a **leased 8,400 square foot facility** in **Smyrna, Georgia**, with the lease scheduled to terminate on **December 31, 2025**[187](index=187&type=chunk) [Legal Proceedings](index=33&type=section&id=ITEM%203.%20LEGAL%20PROCEEDINGS) The company is not currently a party to any material legal proceedings - As of the report date, GeoVax is **not involved in any material legal proceedings**[188](index=188&type=chunk) [Mine Safety Disclosures](index=33&type=section&id=ITEM%204.%20MINE%20SAFETY%20DISCLOSURES) This section is not applicable to the company's operations - **Not applicable**[189](index=189&type=chunk) [Part II](index=33&type=section&id=PART%20II) This section covers the common stock market, stockholder matters, MD&A of financial condition, results of operations, liquidity, and market risk [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=33&type=section&id=ITEM%205.%20MARKET%20FOR%20REGISTRANT%27S%20COMMON%20EQUITY%2C%20RELATED%20STOCKHOLDER%20MATTERS%20AND%20ISSUER%20PURCHASES%20OF%20EQUITY%20SECURITIES) GeoVax common stock trades on Nasdaq under GOVX; the company has never paid and does not anticipate paying cash dividends - The company's common stock is traded on **The Nasdaq Capital Market** under the symbol **"GOVX"**[191](index=191&type=chunk) - GeoVax has **never paid cash dividends** and does not plan to in the foreseeable future[193](index=193&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=ITEM%207.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) GeoVax reported a net loss of $14.0 million in 2022, an improvement from 2021, with cash sufficient to fund operations into Q4 2023 Results of Operations (2022 vs. 2021) | | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Grant and collaboration revenue | $81,526 | $385,501 | $(303,975) | | Research and development | $9,123,479 | $15,554,171 | $(6,430,692) | | General and administrative | $4,986,611 | $3,577,153 | $1,409,458 | | **Loss from operations** | **$(14,028,564)** | **$(18,745,823)** | **$4,717,259** | | **Net loss** | **$(14,021,125)** | **$(18,570,317)** | **$4,549,192** | - Research and development expenses **decreased by 41% to $9.1 million in 2022 from $15.6 million in 2021**. The 2021 figure included **$12.3 million in upfront license fees** for GEO-CM04S1 and Gedeptin. Excluding these one-time costs, R&D expenses **increased by 182% in 2022** due to higher clinical trial, manufacturing, and personnel costs[215](index=215&type=chunk) - General and administrative expenses **increased by 39% to $5.0 million in 2022**, driven by higher personnel, patent, investor relations, and travel costs[216](index=216&type=chunk) Liquidity and Capital Resources Summary | | As of Dec 31, 2022 | As of Dec 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $27,612,732 | $11,423,870 | | Working capital | $24,190,836 | $6,193,756 | - Net cash provided by financing activities was **$35.4 million in 2022**, primarily from offerings of common stock (**$27.7 million**) and the exercise of warrants (**$7.6 million**)[220](index=220&type=chunk) - The company expects its existing cash and cash equivalents will be sufficient to fund operations into the **fourth quarter of 2023**, but will require **substantial additional funding** to continue operations beyond that[222](index=222&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=ITEM%207A.QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company's market risk is limited to interest rate sensitivity on cash and cash equivalents, with no derivative or foreign currency exposure - Market risk is primarily limited to **interest rate sensitivity** on cash and cash equivalents invested in short-term money market funds[225](index=225&type=chunk) - The company does **not use derivative financial instruments** or have **no exposure to foreign currency risk**[225](index=225&type=chunk) [Financial Statements and Supplementary Data](index=39&type=section&id=ITEM%208.%20FINANCIAL%20STATEMENTS%20AND%20SUPPLEMENTARY%20DATA) This section presents consolidated financial statements, including the auditor's report with a going concern emphasis due to recurring losses - The independent auditor's report expresses an opinion that the financial statements are presented fairly, but includes an **"Emphasis of a Matter" paragraph** regarding **"Substantial Doubt about the Company's Ability to Continue as a Going Concern"**[260](index=260&type=chunk) Consolidated Balance Sheet Data (as of Dec 31) | | 2022 | 2021 | | :--- | :--- | :--- | | **Total Assets** | **$31,347,928** | **$11,797,064** | | Total Current Liabilities | $4,747,894 | $5,435,360 | | **Total Liabilities** | **$4,747,894** | **$7,435,360** | | **Total Stockholders' Equity** | **$26,600,034** | **$4,361,704** | Consolidated Statements of Operations Data (Year Ended Dec 31) | | 2022 | 2021 | | :--- | :--- | :--- | | Grant revenue | $81,526 | $385,501 | | Total operating expenses | $14,110,090 | $19,131,324 | | **Net loss** | **$(14,021,125)** | **$(18,570,317)** | | Net loss per common share | $(0.83) | $(3.04) | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=39&type=section&id=ITEM%209.%20CHANGES%20IN%20AND%20DISAGREEMENTS%20WITH%20ACCOUNTANTS%20ON%20ACCOUNTING%20AND%20FINANCIAL%20DISCLOSURE) The company reports no disagreements with its accountants on accounting principles, financial disclosure, or auditing scope - There were **no disagreements with accountants** on accounting and financial disclosure[227](index=227&type=chunk) [Controls and Procedures](index=39&type=section&id=ITEM%209A.CONTROLS%20AND%20PROCEDURES) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022 - Management concluded that as of December 31, 2022, the company's disclosure controls and procedures were **effective**[229](index=229&type=chunk) - Management concluded that as of December 31, 2022, the company's internal control over financial reporting was **effective**[230](index=230&type=chunk) [Part III](index=40&type=section&id=PART%20III) This section covers corporate governance, executive compensation, security ownership, and related party transactions, incorporated by reference from the 2023 proxy statement [Directors, Executive Officers and Corporate Governance](index=40&type=section&id=ITEM%2010.%20DIRECTORS%2C%20EXECUTIVE%20OFFICERS%20AND%20CORPORATE%20GOVERNANCE) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2023 proxy statement - Required information is **incorporated by reference** from the definitive proxy statement for the 2023 annual meeting of stockholders[236](index=236&type=chunk) [Executive Compensation](index=40&type=section&id=ITEM%2011.%20EXECUTIVE%20COMPENSATION) Information regarding executive compensation is incorporated by reference from the company's 2023 annual meeting proxy statement - Required information is **incorporated by reference** from the definitive proxy statement for the 2023 annual meeting of stockholders[239](index=239&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=40&type=section&id=ITEM%2012.%20SECURITY%20OWNERSHIP%20OF%20CERTAIN%20BENEFICIAL%20OWNERS%20AND%20MANAGEMENT%20AND%20RELATED%20STOCKHOLDER%20MATTERS) Security ownership information is incorporated by reference from the 2023 proxy statement, with a table on equity compensation plans - Required information is **incorporated by reference** from the definitive proxy statement for the 2023 annual meeting of stockholders[240](index=240&type=chunk) Securities Authorized for Issuance Under Equity Compensation Plans (as of Dec 31, 2022) | Plan Category | Securities to be issued upon exercise | Weighted-average exercise price | Securities available for future issuance | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by stockholders | 1,158,800 | $2.77 | 166,700 | | Equity compensation plans not approved by stockholders | | | | | Contingent options | 900,000 | $0.76 | -0- | | Management warrants | 272,997 | $5.00 | -0- | [Certain Relationships and Related Party Transactions, and Director Independence](index=41&type=section&id=ITEM%2013.%20CERTAIN%20RELATIONSHIPS%20AND%20RELATED%20PARTY%20TRANSACTIONS%2C%20AND%20DIRECTOR%20INDEPENDENCE) Information on related party transactions and director independence is incorporated by reference from the 2023 proxy statement - Required information is **incorporated by reference** from the definitive proxy statement for the 2023 annual meeting of stockholders[244](index=244&type=chunk) [Principal Accounting Fees and Services](index=41&type=section&id=ITEM%2014.%20PRINCIPAL%20ACCOUNTING%20FEES%20AND%20SERVICES) Information regarding principal accounting fees and services is incorporated by reference from the company's 2023 annual meeting proxy statement - Required information is **incorporated by reference** from the definitive proxy statement for the 2023 annual meeting of stockholders[245](index=245&type=chunk) [Part IV](index=42&type=section&id=PART%20IV) This section lists financial statements, schedules, and exhibits filed with the Form 10-K, including required signatures [Exhibits and Financial Statement Schedules](index=42&type=section&id=ITEM%2015.%20EXHIBITS%20AND%20FINANCIAL%20STATEMENT%20SCHEDULES) This item lists all financial statements, schedules, and exhibits filed with the Form 10-K, including key corporate and contractual documents - This section lists **all documents filed as part of the report**, including **financial statements, schedules, and exhibits** such as material contracts and corporate governance documents[247](index=247&type=chunk)[248](index=248&type=chunk) [Form 10-K Summary](index=44&type=section&id=ITEM%2016.%20FORM%2010-K%20SUMMARY) The company has not provided a summary under this item - **None**[250](index=250&type=chunk)

Financial Data and Key Metrics Changes - The net loss for Q3 2022 was $4 million or $0.17 per share, compared to a net loss of $2 million or $0.31 per share in Q3 2021 [30] - For the nine-month period, the net loss was $8.6 million or $0.63 per share in 2022, compared to $4.8 million or $0.80 per share in 2021 [30] - Cash balances at September 30, 2022, were approximately $35 million, up from $31 million at the end of the last quarter and $1.4 million at the end of 2021 [31] Business Line Data and Key Metrics Changes - Research and development expenses were $2.7 million for Q3 2022, up from $1.2 million in Q3 2021, reflecting increased clinical trial activities for CM04S1 and Gedeptin [29] - General administrative expenses were $1.2 million for Q3 2022, compared to $758,000 in Q3 2021, attributed to higher personnel and consulting costs [30] Market Data and Key Metrics Changes - The company is expanding the CM04S1 COVID-19 vaccine trial among immunocompromised patients to 20-30 centers [37] - Gedeptin is currently in an expanded multi-site evaluation among patients suffering from advanced head and neck cancers, with initial patient enrollment expected to be completed by the end of 2023 [10] Company Strategy and Development Direction - The company aims to provide immunotherapies and vaccines that improve lives worldwide, focusing on cancer and infectious diseases [8] - There is a strong emphasis on accelerating clinical development and expanding patient enrollment for both Gedeptin and CM04S1 [13] - The company is exploring partnerships and collaborations to ensure worldwide access to its products [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of clinical programs and the potential for expedited regulatory review for CM04S1 [12] - The company is well-capitalized to complete its current Phase 2 clinical programs, with a cash runway sufficient to fund operations through the end of next year [32] - Management highlighted the unique position of their vaccine in addressing the needs of immunocompromised individuals, which may lead to expedited regulatory pathways [56] Other Important Information - The company has added $37 million to its balance sheet in 2022, despite a challenging investment environment for the biotech industry [14] - The modified vaccinia Ankara (MVA) vaccine vector is being utilized for both COVID-19 and monkeypox, with promising results in preclinical studies [25] Q&A Session Summary Question: Expansion of COVID-19 immunocompromised trial centers - Management plans to expand to 20-30 centers for the trial [37] Question: Status of monkeypox indication - There is a clear regulatory pathway for adding monkeypox and smallpox indications to the MVA platform vaccine [39] Question: Progress from head and neck centers and ASH attendance - The ongoing Gedeptin trial is now involved with three academic medical centers, with full enrollment anticipated by early next year [42] Question: Competitor results and implications for immunocompromised individuals - The MVA vaccine is effective for immunocompromised patients, with a unique niche in driving antiviral responses [48] Question: Current environment for COVID vaccines and regulatory paths - Management anticipates clarifying regulatory pathways as they engage with the FDA based on trial data [60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Driv ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John Sharkey – Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Jeff Kraws - Crystal Research Kumarguru Raja - Brookline Capital Markets Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 87-0455038 (State or other jurisdiction (IRS Employer Identification No.) 1900 Lake Pa ...

Financial Data and Key Metrics Changes - Grant and Collaboration revenues decreased to $385,000 in 2021 from $1.8 million in 2020, primarily due to the winding down of a grant from the U.S. Army [29][30] - Research and development expenses increased significantly to $15.6 million in 2021 from $2.4 million in 2020, driven by license fees and clinical trial expenses related to COVID-19 vaccine programs [31] - General and Administrative expenses rose to $3.6 million in 2021 from $2.2 million in 2020, largely due to increased franchise tax and other operational costs [32] - The overall net loss for 2021 was $18.6 million or $3.04 per share, compared to a net loss of $3 million or $2.14 per share in 2020 [33] Business Line Data and Key Metrics Changes - The company advanced its Phase 2 clinical development for both COVID-19 and immuno-oncology, with a focus on the CM04S1 and Gedeptin programs [6][9] - CM04S1 is a next-generation COVID-19 vaccine designed to elicit both antibody and T-cell responses, currently in two Phase 2 clinical trials [20][24] - Gedeptin, a cancer immunotherapy, is being evaluated in patients with advanced head and neck cancers and has received orphan drug status from the FDA [7][17] Market Data and Key Metrics Changes - The company reported encouraging results in its hemorrhagic fever virus vaccine program, with ongoing discussions with BARDA regarding potential funding for clinical studies [12][58] - The company is also exploring opportunities for the Gedeptin program in combination with checkpoint inhibitors for enhanced treatment efficacy [18][80] Company Strategy and Development Direction - The company aims to accelerate recruitment and enrollment in its Phase 2 programs, with a focus on expanding clinical trial sites for Gedeptin [14][15] - The strategy includes enhancing resources and expertise to support growth and development plans for 2022 and beyond [13] - The company is committed to developing a manufacturing process to increase production consistency and capacity for its vaccine programs [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the need for next-generation vaccines to address emerging COVID-19 variants and the inadequacies of current vaccines for high-risk populations [44][46] - The company anticipates reporting milestones and progress related to its clinical and IND enabling programs throughout the year [12][66] Other Important Information - The company has strengthened its balance sheet, with cash balances of approximately $17 million as of early 2022, sufficient to fund operations into the second quarter of 2023 [35][37] - The company is focused on creating attractive investment opportunities as it advances its clinical programs [37] Q&A Session Summary Question: What is the state of COVID vaccines and the importance of the CM04S1 program? - Management acknowledged the ongoing emergence of variants and the need for vaccines that elicit both antibody and T-cell responses to provide better protection [44][45] Question: What are the plans for the Sudan and Marburg programs? - Management indicated ongoing dialogue with BARDA and anticipated support for clinical development based on encouraging preclinical results [58][60] Question: What are the expectations for the Gedeptin program in terms of patient enrollment and response rates? - Management noted that five patients have been enrolled and speculated that a response rate of 20% to 30% would be considered significant for regulatory discussions [76][81]